Table 2.

Selective Actively Recruiting Clinical Trials for patients

Name of study Clinical	Phase	Conditions	Therapy	Measure	Clinicaltrials.gov Identifier
A Study of ALKS 4230 on the TME	Phase 2	Advanced Solid cancer	ALKS 4230 + pembrolizumab	Total T cells, CD8+ T cells, CD56+ cells and Treg cells	NCT04592653
Effects of MK-3475 (Pembrolizumab) on the Breast TME in Triple Negative Breast Cancer		Triple Negative Breast Cancer	Merck 3475 Pembrolizumab	Number of subjects with significant mean percent change in TILs	NCT02977468
Analysis of the Modulation of the TME by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)	Phase 2	Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting	Pembrolizumab - additional treatment	Bioinformatics	NCT03534635
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer	Phase 2	Pancreatic Cancer	Cyclophosphamide	CD8 count (cells/mm^3) in the TME	NCT03161379
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer	Phase 1/Phase 2	Pancreas Cancer	L-DOS47 Plus Doxorubicin	Cancer pH, Proportion of patients expressing anti-L-DOS47 antibodies	NCT04203641